Biohaven Pharma (BHVN) Misses Q3 EPS by 10c

Biohaven Pharma (NYSE: BHVN) reported Q3 EPS of ($1.44), $0.10 worse than the analyst estimate of ($1.34). Revenue for the quarter came in at $0.

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
• Crown Crafts (CRWS) Reports Q4 EPS of $0.03